MX2022014250A - Vacuna recombinante contra covid-19 en vector viral de paramixovirus. - Google Patents

Vacuna recombinante contra covid-19 en vector viral de paramixovirus.

Info

Publication number
MX2022014250A
MX2022014250A MX2022014250A MX2022014250A MX2022014250A MX 2022014250 A MX2022014250 A MX 2022014250A MX 2022014250 A MX2022014250 A MX 2022014250A MX 2022014250 A MX2022014250 A MX 2022014250A MX 2022014250 A MX2022014250 A MX 2022014250A
Authority
MX
Mexico
Prior art keywords
viral vector
recombinant vaccine
vaccine against
against covid
paramyxovirus viral
Prior art date
Application number
MX2022014250A
Other languages
English (en)
Inventor
Peter Palese
Florian Krammer
Adolfo Garcia-Sastre
Ernesto Soto-Priante
David Sarfati-Mizrahi
Bernardo Lozano-Dubernard
Weina Sun
Felipa Castro-Peralta
La Rosa Georgina Paz-De
Original Assignee
Laboratorio Avi Mex S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorio Avi Mex S A De C V filed Critical Laboratorio Avi Mex S A De C V
Publication of MX2022014250A publication Critical patent/MX2022014250A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18161—Methods of inactivation or attenuation
    • C12N2760/18162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe una vacuna recombinante, activa o inactivada, contra COVID-19 que comprende un vector viral de la enfermedad de Newcastle y un vehículo, adyuvante y/o excipiente farmacéuticamente aceptable, caracterizada porque el vector viral es un virus capaz de generar una respuesta inmune celular y tiene insertada una secuencia de nucleótidos exógena de SARS-CoV-2.
MX2022014250A 2020-05-13 2021-02-22 Vacuna recombinante contra covid-19 en vector viral de paramixovirus. MX2022014250A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2020/054545 WO2021229270A1 (es) 2020-05-13 2020-05-13 Vacuna recombinante contra covid-19 en vector viral
PCT/IB2021/051491 WO2021229311A1 (es) 2020-05-13 2021-02-22 Vacuna recombinante contra covid-19 en vector viral de paramixovirus

Publications (1)

Publication Number Publication Date
MX2022014250A true MX2022014250A (es) 2022-12-07

Family

ID=78525379

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014250A MX2022014250A (es) 2020-05-13 2021-02-22 Vacuna recombinante contra covid-19 en vector viral de paramixovirus.

Country Status (15)

Country Link
US (1) US20230226171A1 (es)
EP (1) EP4151232A1 (es)
JP (1) JP2023526309A (es)
KR (1) KR20230010663A (es)
CN (1) CN116710563A (es)
AR (1) AR122062A1 (es)
AU (1) AU2021269903A1 (es)
BR (1) BR112022023096A2 (es)
CA (1) CA3178542A1 (es)
CO (1) CO2022017623A2 (es)
IL (1) IL298080A (es)
MX (1) MX2022014250A (es)
PE (1) PE20230766A1 (es)
UY (1) UY39208A (es)
WO (2) WO2021229270A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20210318A1 (es) * 2021-01-08 2021-02-16 Farm Veterinarios S A C Composicion inmunogenica viva recombinante que comprende el virus de la enfermedad de newcastle (ndv) que expresa la subunidad s1 y el rbd de la proteina spike del sars-cov-2

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030224017A1 (en) 2002-03-06 2003-12-04 Samal Siba K. Recombinant Newcastle disease viruses useful as vaccines or vaccine vectors
AP2911A (en) 2005-12-02 2014-05-31 Sinai School Medicine Chimeric Viruses presenting non-native surface proteins and uses thereof
EP2501404A1 (en) 2009-11-16 2012-09-26 Stichting Dienst Landbouwkundig Onderzoek Use of newcastle disease virus-based vector for inducing an immune response in mammals
JOP20190256A1 (ar) * 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
US10689716B1 (en) * 2020-03-19 2020-06-23 University Of Miami Materials and methods for detecting coronavirus
CN112011521A (zh) * 2020-06-15 2020-12-01 浙江迪福润丝生物科技有限公司 一种重组新城疫病毒载体新型冠状病毒疫苗候选株及其构建方法和应用

Also Published As

Publication number Publication date
KR20230010663A (ko) 2023-01-19
PE20230766A1 (es) 2023-05-09
JP2023526309A (ja) 2023-06-21
WO2021229270A1 (es) 2021-11-18
CO2022017623A2 (es) 2022-12-20
US20230226171A1 (en) 2023-07-20
IL298080A (en) 2023-01-01
CA3178542A1 (en) 2021-11-18
EP4151232A1 (en) 2023-03-22
BR112022023096A2 (pt) 2022-12-20
AU2021269903A1 (en) 2022-12-15
UY39208A (es) 2021-12-31
WO2021229311A1 (es) 2021-11-18
AR122062A1 (es) 2022-08-10
CN116710563A (zh) 2023-09-05

Similar Documents

Publication Publication Date Title
MX2022014250A (es) Vacuna recombinante contra covid-19 en vector viral de paramixovirus.
MX2021015465A (es) Vacuna para fiebre porcina africana.
TR200200838T2 (tr) İmmunolojik olarak önemli herpes simpleks virüs antijenleri.
DK0538437T3 (da) Immunstimulerende og immunforstærkende, rekonstituerede influenzavirosomer og vacciner indeholdende dem
JP2014520117A5 (es)
WO2018140766A3 (en) Porcine coronavirus vaccines
BRPI0909547A2 (pt) vacina combinada de sarampo - hpv, vetor e hospedero
AP2000001841A0 (en) Method for obtaining vaccines for preventing the pathgenic effects related to a retroviral infection.
RU2018130813A (ru) Вакцины против fmdv на основе рекомбинантного аденовирусного вектора и их применение
MX2022003590A (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9.
WO2014205579A4 (en) Modified matrix proteins of vesicular stomatitis virus
TW377373B (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline infectious peritonitis virus disease
WO2023042181A9 (en) Recombinant vaccine against covid-19 to produce cellular response in individuals with pre-existing immunity
MX2023000884A (es) Vacuna que usa vectores de influenza deficientes en m2/bm2.
MX2022002270A (es) Vacunas contra el virus de la hepatitis b.
CL2022003150A1 (es) Vacuna recombinante contra covid-19 en vector viral de paramixovirus
WO2004009763A3 (en) Use of vaccinia virus deleted for the e3l gene as a vaccine vector
EP1439856A4 (en) RECOMBINANT TOLLWOOD VACCINES AND METHOD FOR THEIR PREPARATION AND USE
JP2012529427A (ja) 免疫接種のための発現ベクターとしての水疱性口内炎ウイルスの異なる複数の抗原型
WO2022266511A8 (en) Temperature-controllable, self-replicating rna vaccines for viral diseases
WO2022191801A3 (en) Integrase defective hiv-based lentivirus mediated new generation covid-19 vaccine encoding sars-cov-2 spike protein
JP6373601B2 (ja) アカバネウイルスに対して中和活性を有する抗体を誘導するペプチド
DE60330795D1 (de) Impfstoff gegen west nile virus
WO2001092548A3 (en) Vaccine and gene therapy vector and methods of use thereof
MX2013012994A (es) Vacuna recombinante contra el sindrome reproductivo y respiratorio porcino en vector viral.